Rosmarinic acid, a major polyphenolic component of Perilla frutescens, reduces lipopolysaccharide (LPS)-induced liver injury in D-galactosamine (D-GalN)-sensitized mice. 2002

Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
Functional Foods Research and Development Laboratory, Meiji Seika Kaisha Ltd., Chiyoda Sakado, Japan. naomi_osakabe@meiji.co.jp

The protective activity of rosmarinic acid from Perilla frutescens on liver injury induced by LPS in D-GalN-sensitized mice was examined. We also investigated the effects of antitumor necrosis factor-alpha antibody (anti-TNF), superoxide dismutase (SOD), and aminoguanidine (AG) on this model in order to elucidate the mechanism of rosmarinic acid protection. Perilla extract (PE) and rosmarinic acid (RA) treatments significantly reduced the elevation of plasma asparatate aminotransferase levels, as well as anti-TNF and SOD treatment, compared with controls, but this reduction was not seen in the AG group. These results were confirmed by histological examination using hematoxylin-eosin and in situ terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining. Increases in tumor necrosis factor-alpha (TNF-alpha) mRNA expression in liver and in plasma TNF-alpha levels, which were observed in control mice, were not significantly reduced by PE or RA. PE and RA treatments also did not significantly diminish iNOS mRNA expression or plasma nitrate/nitrite levels. Nitrotyrosine and N(epsilon)-(hexanonyl)lysine (HEL) production, the residue of oxidative stress, was observed in livers from controls, but not in those mice pretreated with PE or RA. These results suggest that the liver protection of RA is due to the scavenging or reducing activities-superoxide or peroxynitirite rather than to inhibition of TNF-alpha production.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008956 Models, Chemical Theoretical representations that simulate the behavior or activity of chemical processes or phenomena; includes the use of mathematical equations, computers, and other electronic equipment. Chemical Models,Chemical Model,Model, Chemical
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D002934 Cinnamates Derivatives of cinnamic acid (the structural formula: phenyl-HC Cinnamate
D005688 Galactosamine
D000097123 Rosmarinic Acid A polyphenol compound that naturally occurs in rosemary with ANTIOXIDANT and anti-inflammatory properties. Rosemary Acid,Rosmarinate,Rosmarinic Acid, (R-(E))-Isomer,Acid, Rosemary,Acid, Rosmarinic
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic

Related Publications

Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
May 2008, Digestive diseases and sciences,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
July 2007, Toxicology,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
May 2001, The Journal of nutrition,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
June 2010, European journal of pharmacology,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
June 2018, Microbial pathogenesis,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
August 2011, Journal of agricultural and food chemistry,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
November 2007, Acta pharmacologica Sinica,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
September 1996, Gastroenterology,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
December 2018, Microbial pathogenesis,
Naomi Osakabe, and Akiko Yasuda, and Midori Natsume, and Chiaki Sanbongi, and Yoji Kato, and Toshihiko Osawa, and Toshikazu Yoshikawa
July 2019, International immunopharmacology,
Copied contents to your clipboard!